Streetbeat News

STSS

Sharps Technology, Inc.

Industry

Medical - Instruments & Supplies

Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.

Open

2.86

Mkt cap

4.8M

Volume

27K

High

2.86

P/E Ratio

-0.25

52-wk high

18.15

Low

2.65

Div yield

N/A

52-wk low

2.34

Shares of Sharps Technology, Inc. (NASDAQ:STSS) surged 31.7% in pre-market trading after receiving two purchase orders for approximately one million SecureGard syringes for 2024 delivery. Other notable pre-market movers include Qualigen Therapeutics, Inc. (NASDAQ:QLGN) up 53%, Maxeon Solar Technologies, Ltd. (NASDAQ:MAXN) up 18.7%, and Adamas One Corp. (NASDAQ:JEWL) down 19.3%.

Portfolio Pulse from Avi Kapoor

July 05, 2024 | 3:01 pm

The article highlights significant intraday movements in health care stocks on Thursday. Notable gainers include Qualigen Therapeutics (QLGN), Sharps Technology (STSS), and Autonomix Medical (AMIX), while Reshape Lifesciences (RSLS) and CNS Pharma (CNSP) were among the losers.

Portfolio Pulse from Benzinga Insights

July 05, 2024 | 3:00 pm

Sharps Technology shares are trading higher after the company announced it received two purchase orders for a total of approximately one million SecureGard syringes for 2024 delivery.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 5:07 pm

Sharps Technology, Inc. (NASDAQ: STSS) has received purchase orders for 1 million SecureGard ultra-low waste smart safety syringes from a Swiss-based provider of injectable therapies. The first 100k units will be shipped in late July, with the rest delivered throughout Q3 and Q4 of 2024. This marks the beginning of a potential long-term partnership.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 5:06 pm

Sharps Technology has shipped its first orders for Securegard disposable smart safety syringes, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:35 pm

U.S. stocks traded mixed with the S&P 500 edging higher. Signet Jewelers' shares fell 16% due to mixed first-quarter earnings. BioRestorative Therapies, Zapp Electric Vehicles, and Sharps Technology saw significant gains. J.Jill, Nuburu, and Cara Therapeutics experienced notable declines.

Portfolio Pulse from Avi Kapoor

June 13, 2024 | 6:35 pm

Signet Jewelers Limited (NYSE:SIG) shares fell over 12% due to mixed first-quarter earnings, including a significant drop in same-store sales. The company reported a 9.5% year-on-year sales decline, missing analyst estimates, but beat EPS expectations. Other stocks mentioned include BioRestorative Therapies, Zapp Electric Vehicles, Sharps Technology, and Broadcom, among others, with various gains and losses based on recent announcements and earnings reports.

Portfolio Pulse from Avi Kapoor

June 13, 2024 | 6:07 pm

The article highlights significant intraday movements in healthcare stocks on Thursday. Longeveron, BioRestorative Therapies, Aethlon Medical, Sharps Technology, Biomea Fusion, and iSpecimen saw notable gains, while Assure Holdings, CERo Therapeutics Holdings, Cara Therapeutics, Kronos Bio, Cyclerion Therapeutics, and Petros Pharma experienced declines.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 4:31 pm

U.S. stocks traded mixed with the Dow Jones down over 200 points, while the NASDAQ rose. Broadcom shares surged 13% after strong Q2 results and a 10-for-1 stock split announcement. BioRestorative Therapies, Zapp Electric Vehicles, and Sharps Technology saw significant gains. J.Jill, Nuburu, and Cara Therapeutics experienced notable declines.

Portfolio Pulse from Avi Kapoor

June 13, 2024 | 4:07 pm

Sharps Technology Inc. (NASDAQ:STSS) shares surged after the company signed a $30 million purchase order with Nephron Pharmaceuticals. This order is part of a larger five-year, $200 million syringe sales agreement. The deal is expected to close by the end of July.

Portfolio Pulse from Erica Kollmann

June 13, 2024 | 3:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.